|
 |
|
|
|
| |
|
|
|
|
| Table 7. HIV-infected patients currently prescribed highly active antiretroviral therapy (HAART) by
data source and sex
|
|
|
|
|
View PDF
|
|
Data in Tables 6-8 are based on the following analyses:
- Among patients eligible according to guidelines in place in 1999, what is the proportion of patients prescribed highly active antiretroviral therapy1 (HAART) in ASD in 1999 and SHDC in 1998?
|
 |
|
|
|
|
|
|
|
|
| Data Source |
Total |
|
Male |
|
Female |
| % |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
| ASD |
61 |
5,479/8,923 |
|
62 |
4,074/6,520 |
|
58 |
1,405/2,403 |
| SHDC Site A |
68 |
166/242 |
68 |
104/157 |
67 |
74/99 |
| SHDC Site B |
64 |
111/171 |
64 |
73/114 |
66 |
38/57 |
| SHDC Site C |
69 |
161/249 |
75 |
138/184 |
51 |
32/63 |
|
|
|
|
*Persons with unknown insurance status were not included. |
- Among patients eligible for ART, similar proportions of males compared with females were currently prescribed HAART at SHDC Sites A and B. In ASD and SHDC Site C, greater proportions of males were currently prescribed HAART compared with females.
- Differences in the populations represented by the samples at the 3 SHDC sites may account for the difference in HAART prescription by sex (see Technical Notes).
- Providers at Sites A and B may provide more HIV-related care to females and may be more likely to prescribe HAART compared with providers not in or near metropolitan areas at Site C.
Data from the SHAS and MOPTB studies were not available for this question.
|
|
|
|
|
|
|
|
|
|
|
